3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Status
Active not recruiting
3
Completed
1
Sponsor Class
OTHER
27
INDUSTRY
4
OTHER_GOV
1
NIH
1
Study Type
Interventional
4
Sponsor
Cancer Type
Other hematologic neoplasm
2
Gynecologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
926
Neoplasms
609
Breast Neoplasms
604
Colorectal Neoplasms
457
Neoplasm Metastasis
394
Ovarian Neoplasms
328
Melanoma
312
Prostatic Neoplasms
311
Lung Neoplasms
294
Multiple Myeloma
290
Recurrence
278
Squamous Cell Carcinoma of Head and Neck
246
Stomach Neoplasms
229
Pancreatic Neoplasms
228
Leukemia, Myeloid, Acute
220
Triple Negative Breast Neoplasms
190
Endometrial Neoplasms
190
Carcinoma, Renal Cell
182
Lymphoma, Non-Hodgkin
179
Carcinoma, Hepatocellular
177
Small Cell Lung Carcinoma
165
Leukemia, Lymphocytic, Chronic, B-Cell
156
Advanced Solid Tumors
154
Lymphoma, Follicular
148
Urinary Bladder Neoplasms
139
Lymphoma, Large B-Cell, Diffuse
138
Lymphoma
137
Advanced Solid Tumor
137
Uterine Cervical Neoplasms
134
Head and Neck Neoplasms
134
Interventions
Azacitidine
2
venetoclax
1
sargramostim
1
rucaparib
1
olaparib
1
cc-486
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Decitabine
1
Cytarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pathologic Complete Response
×
1 year
×
Clear all
NCT01844986
2025-12-10
SOLO-1
AstraZeneca
Phase 3
Active not recruiting
450 enrolled
18 charts
1 FDA
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA
NCT03522246
2025-06-24
ATHENA
pharmaand GmbH
Phase 3
Active not recruiting
1,097 enrolled
26 charts